Original Article

Novel genetic variants are associated with increased vertebral volumetric BMD, reduced vertebral fracture risk, and increased expression of SCL1A3 and EPHB2


1School of Public Health, Oregon Health & Science University, Portland, OR, USA
2Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
3Icelandic Heart Association, Kópavogur, Iceland
4Faculty of Medicine, University of Iceland, Reykjavík, Iceland
5Department of Orthopaedics and Rehabilitation, University of Rochester, Rochester, NY, USA
6Department of Medical Biochemistry, Oslo University Hospital, Ullevål, Oslo, Norway
7Lovisenberg Diakonale Hospital, Oslo, Norway
8Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
9Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington, VT, USA
10Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA
11Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
12Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging (NCHA), Leiden, The Netherlands
13Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
14Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
15California Pacific Medical Center Research Institute, San Francisco, CA, USA
16Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA
17National Institute on Aging (NIA), National Institutes of Health, Bethesda, MD, USA

*This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/jbmr.2913]

Additional Supporting Information may be found in the online version of this article.

Initial Date Submitted April 13, 2016; Date Revision Submitted June 22, 2016; Date Final Disposition Set July 8, 2016

Journal of Bone and Mineral Research
This article is protected by copyright. All rights reserved
DOI 10.1002/jbmr.2913
18Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
19Department of Radiology, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
20Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA
21Department of Neurology, Boston University, Boston, MA, USA
22Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University Medical School, Boston, MA, USA
23Broad Institute of MIT and Harvard, Cambridge, MA, USA;
24Technical University Munich, Munich, Germany
25Imaging, Icelandic Heart Association, Kópavogur, Iceland
26Department of Bioinformatics, Gothenburg University, Gothenburg, Sweden
27Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
28Public Health Sciences Wake Forest School of Medicine, Winston-Salem, NC, USA
29Center for Human Genomics and Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
30Center for Human Genomics and Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
31Department of Radiology & Radiological Sciences, Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA
32Center for Diabetes Research, Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
33Department of Family Medicine and Public Health, University of California, San Diego (UCSD), La Jolla, CA, USA
34Internal Medicine/Endocrinology, Wake Forest School of Medicine, Winston-Salem, NC, USA
35Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA
36Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
37Department of Orthopaedics and Clinical Sciences, Malmö University Hospital, Lund University, Malmö, Sweden
38Los Angeles Biomedical Research Institute, Torrance, CA, USA
39Rheumatic Diseases Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK
40Lovisenberg Diakonale Hospital, Oslo, Norway
41Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
42Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel
43Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
44Division of Endocrinology, Oregon Health & Science University, Portland, OR, USA
45Molecular and Integrative Physiological Sciences, Harvard School of Public Health, Boston, MA, USA

Address correspondence to: Carrie M Nielson, MPH, PhD, School of Public Health, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, CR113, Portland, OR 97239, USA. E-mail: nielsoca@ohsu.edu

*CMN, DPK, and Y-HH contributed equally to this work.
ABSTRACT

Genome-wide association studies (GWAS) have revealed numerous loci for areal bone mineral density (aBMD). We completed the first GWAS meta-analysis (N=15,275) of lumbar spine volumetric BMD (vBMD) measured by quantitative computed tomography (QCT), allowing for examination of the trabecular bone compartment. SNPs that were significantly associated with vBMD were also examined in two GWAS meta-analyses to determine associations with morphometric vertebral fracture in (N=21,701) and clinical vertebral fracture (N=5,893). Expression QTL analyses of iliac crest biopsies were performed in 84 postmenopausal women, and murine osteoblast expression of genes implicated by eQTL or by proximity to vBMD-associated SNPs was examined. We identified significant vBMD associations with five loci, including 1p36.12, containing WNT4 and ZBTB40; 8q24, containing TNFRSF11B; and 13q14, containing AKAP11 and TNFSF11. Two loci (5p13 and 1p36.12) also contained associations with radiographic and clinical vertebral fracture, respectively. In 5p13, rs2468531 (minor allele frequency [MAF]=3%) was associated with higher vBMD (β = 0.22, p = 1.9 x 10^{-8}) and decreased risk of radiographic vertebral fracture (OR = 0.75; false discovery rate [FDR] p = 0.01). In 1p36.12, rs12742784 (MAF=21%) was associated with higher vBMD (β = 0.09, p = 1.2 x 10^{-10}) and decreased risk of clinical vertebral fracture (OR =0.82; FDR p = 7.4 x 10^{-4}). Both SNPs are non-coding and were associated with increased mRNA expression levels in human bone biopsies: rs2468531 with SLC1A3 (β = 0.28, FDR p = 0.01, involved in glutamate signaling and osteogenic response to mechanical loading) and rs12742784 with EPHB2 (β = 0.12, FDR p = 1.7 x 10^{-3}, functions in bone-related ephrin signaling). Both genes are expressed in murine osteoblasts. This is the first study to link SLC1A3 and EPHB2 to clinically relevant vertebral osteoporosis phenotypes. These results may help elucidate vertebral bone biology and novel approaches to reducing vertebral fracture incidence.

This article is protected by copyright. All rights reserved

KEY WORDS: BONE QCT/µCT; ANALYSIS/QUANTITATION OF BONE; OSTEOPOROSIS; DISEASES AND DISORDERS OF/RELATED TO BONE; GENERAL POPULATION STUDIES; EPIDEMIOLOGY, HUMAN ASSOCIATION STUDIES; GENETIC RESEARCH; FRACTURE RISK ASSESSMENT; PRACTICE/POLICY-RELATED ISSUES
INTRODUCTION

Vertebral osteoporosis and fracture are substantial sources of pain, height loss, and mobility limitation in older adults (1). Not only has the burden of these conditions increased with the aging of populations, but the age-specific incidence of vertebral fracture has risen or remained steady even as the incidence of hip and other osteoporotic fractures has declined (2-4). Risk of fracture correlates with lower vertebral bone mineral density (BMD) (5) that declines with age, leaving the bone susceptible to compression and deformation even in the absence of traumatic force.

Both vertebral BMD and fracture are heritable (6) and multiple genetic loci have been associated with BMD as determined by dual x-ray absorptiometry (DXA) through large-scale GWAS meta-analyses (7,8). Far fewer loci — either from BMD candidate genes or from GWAS — have been linked to fracture risk, even in large samples (9,10). This is likely due to several factors, including the multifactorial causation of fracture, heterogeneity of fracture risk by skeletal sites, and the inability of DXA BMD to completely define bone strength and fracture risk.

Vertebral bone is unique in that its source of strength comes to a large extent from the trabecular compartment, with relatively little cortical area compared to other load-bearing skeletal sites. Quantitative computed tomography (CT) of the vertebrae allows for volumetric BMD measures of the trabecular compartment specifically, which are more strongly associated with vertebral fracture than areal BMD measures (11). Areal BMD measured by DXA is confounded by bone size. In contrast with DXA, CT-based measurements of the spine allow for exclusion of vertebral elements and artifacts, including osteophytic or extra-skeletal calcification that is common in older adults (12,13). For these reasons, we undertook a GWAS meta-analysis of quantitative CT-based volumetric BMD in the lumbar spine in older men and women, and we evaluated the resulting associations in separate meta-analyses of vertebral fracture.

METHODS

Study Design and Participants

Cohort design and characteristics are described in Supplemental Table 1.

Discovery studies: Six cohorts of men and women of European descent with CT imaging of the L2 or L3 spine were included in a discovery meta-analysis of trabecular volumetric BMD (vBMD, N=12,287). Discovery cohorts included Age Gene/Environment Susceptibility-Reykjavik Study (AGES-Reykjavik)(14), Framingham Osteoporosis Study (6,15), Family Heart Study, Health Aging and Body Composition (Health ABC), Multi-Ethnic Study of Atherosclerosis (MESA)(16), and
Osteoporotic Fractures in Men (MrOS)(17). Except for Health ABC, the cohorts also had an integral vBMD (N=11,080) phenotype at the same lumbar vertebra. All participants were adults, and the mean age in each cohort ranged from 52 to 76 years (Supplemental Table 1).

**Replication studies:** Replication of trabecular vBMD associations were done *in silico* in the Diabetes Heart Study (DHS, N=967) and with de-novo genotyping on selected SNPs in an additional sample from the AGES-Reykjavik cohort (N=2,020).

**Fracture studies:** Two of the discovery cohorts (Framingham and MrOS) and five additional cohorts (MrOS-Sweden, Rotterdam I-III, Study of Osteoporotic Fractures [SOF]) contributed to the evaluation of trabecular vBMD-associated loci for their association with radiographic vertebral fracture (N=21,701; 23% fracture cases).

**Lumbar Spine CT Phenotypes**

CT scans of the spine provided vBMD phenotypes at either L2 or L3 (Figure 1). In cohorts with vBMD measured at adjacent levels, correlations were high (r=0.89-0.93). CT scanners and software used in each cohort are listed in Supplemental Table 1. In MESA, CT data were analyzed using Image Analysis Volumetric Software, and the remaining cohorts were analyzed using software developed by one author (TL).(18) In order to ensure regions of interest were defined consistently across cohorts, two authors (TL and MB) evaluated phenotype definitions. The tissue density of the analyzed volume calibrated to units of equivalent concentration of hydroxyapatite in g/cm³ yielded the BMD values. The following two BMD phenotypes were analyzed:

*Trabecular volumetric BMD* *(vBMD)* is the average density in g/cm³ of all the voxels contained within the boundary of the trabecular region. This measure was calculated from a single slice of the region encompassing most of the trabecular bone in the vertebral body (Figure 1).

*Integral vBMD* is the average density in g/cm³ of all the voxels contained within the periosteal edge of the vertebral body, excluding all of the posterior elements (Figure 1).

**Vertebral Fracture Phenotypes**

Two separate fracture GWAS meta-analyses were conducted on non-overlapping population samples. Radiographic vertebral fracture is often asymptomatic and was evaluated by imaging in cohort studies of older men and women (described below). On the other hand, clinical vertebral fracture was
defined (as described in the attached manuscript by Lopez et al.) by signs and symptoms such as back pain, height loss, and kyphosis and was confirmed by imaging.

**Radiographic vertebral fracture:** These studies included prevalent and incident fracture evaluated from T4 to L4. Prevalent radiographic vertebral fracture was defined for each cohort as described in Supplemental Table 1. Prevalent vertebral fracture was defined by Genant’s scale (19) or by using vertebral body height ratios >3SD (20, 21), evaluated by visual semi-quantitative readings or quantitative assessments with review by a radiologist. In three cohorts (MrOS (22), Rotterdam I and II), incident radiographic vertebral fracture was also included in the case definition. Between 15% and 22% of each cohort were cases.

**Clinical vertebral fracture:** Nine clinic- or population-based case-control or cohort studies were included in the GWAS of this phenotype. All participants were postmenopausal women age 45 or older from Europe or Australia. Cases were matched with controls from the same geographical region or same ethnic background.

**Genotyping and Imputation**

Genome-wide genotyping was followed by imputation of non-genotyped SNPs up to 2.7 million SNPs using the HapMap II reference panels. Details of each cohort’s genotyping and imputation methods are provided in Supplemental Table 2. Replication genotyping for 13 SNPs in the AGES cohort was done using TaqMan at LGC Genomics.

**Statistical Analysis**

Association analyses were performed in each study first and then meta-analyses were applied to combine results from each study. Within each study, a z-score transformation of BMD phenotypes was applied. A general linear regression model with the additive genetic effect was applied to test for association between each BMD phenotype (Z-score) and each autosomal SNP. In the regression model, we adjusted for age, age², weight (kg), and principal components for ancestral genetic background and study specific covariates (such as study site). In mixed-sex cohorts, sex was included as an adjustment variable in the regression model. Sex-stratified results were also provided. In the Framingham Osteoporosis Study and the Family Heart Study, a linear mixed effects model with within-family correlations as a random effect was used to account for relatedness among participants. In the Diabetes Heart Study, a random effects model was implemented using Sequential Oligogenic Linkage
Analysis Routines (SOLAR) version 6.3.4 (Texas Biomedical Research Institute, San Antonio, TX, USA) as previously described (23,24). The kinship coefficient matrix used was verified by the genotypic data via the software KING. The fixed-effect inverse-variance meta-analyses were performed by two authors (YH and CN) independently. Meta-analysis results were filtered by sample size (< half of the total sample size), number of studies with available results (< 3 cohort studies), overall MAF (< 1%) and the heterogeneity test across studies ($I^2 \geq 50$ or p-values for heterogeneity $\chi^2$ test $q < 5 \times 10^{-5}$). Genome-wide significance (GWS) level was defined as p-value $< 5 \times 10^{-8}$, and suggestive significance level was defined as $p < 5 \times 10^{-6}$ after adjusting for genomic control $\lambda_{GC}$ value within each cohort and after meta-analysis. Double genomic control was applied to the integral vBMD GWAS after observing an elevated $\lambda_{GC}$ value. Q-Q and Manhattan plots were generated in R 3.2.2 using plyr and qqman packages (Supplemental Figures 1 and 2). For GWS and suggestive SNPs, effect sizes were evaluated for heterogeneity between sexes using fixed-effect inverse-variance meta-analysis.

**Conditional associations:** To identify whether SNPs that were associated with trabecular vBMD or integral vBMD were independent from (not in LD with) SNPs that were reported to be associated with DXA BMD at the lumbar spine, (8) we performed a conditional analysis using the GCTA (Genome-wide Complex Trait Analysis) tool package. (25,26) For GWS and suggestive loci, we conditioned on reported BMD GWAS SNPs (associated with lumbar spine BMD measured by DXA). We selected SNPs for replication genotyping that were associated with CT BMD (trabecular vBMD or integral vBMD) independently from SNPs associated with DXA BMD based on conditional analyses. After genotype quality control, thirteen SNPs were available for inclusion in meta-analyses of discovery and replication.

**Association with radiographic vertebral fracture:** The most significant SNP at each GWS or suggestive trabecular vBMD locus (n=12) was evaluated for its association with radiographic vertebral fracture using logistic regression, with results combined across cohorts using fixed-effect inverse-variance meta-analysis. In each cohort, adjustments for age, height, and weight were performed. In mixed-sex cohorts, sex adjustment was also included. In addition, results for each of the 12 SNPs were examined in an independent meta-analysis of clinical vertebral fracture (N=5,893, Lopez et al., submitted manuscript attached to this submission for your review). False-discovery rate p-values were calculated, and the direction of effect relative to that for trabecular vBMD was used to evaluate consistency across phenotypes (e.g., an OR>1 for fracture is consistent with a negative $\beta$ for trabecular vBMD).
Expression Quantitative Trait Loci (eQTLs) Analysis

We conducted cis-expression quantitative trait locus (eQTL) analysis within a 2Mb flanking region (1Mb upstream and 1 Mb downstream) of each of the top SNPs to evaluate whether they influence transcript levels of genes in human pelvic crest bone biopsies (27) and human primary osteoblasts. Expression experiments in human whole bone biopsies and human primary osteoblasts were conducted in different study samples. For details of genotyping and microarray expression profiling, see Supplemental Methods. For eQTL analyses, a linear regression model with the additive genetic effect was used. We adjusted for age, weight, cigarette smoking and genetic ancestry in the regression model. Locus-wide statistical significance was defined as false discovery rate (FDR) Q-values < 0.05 in each locus.

Primary Murine Osteoblasts

Gene expression profiles of six candidate genes near genome-wide associated SNPs were examined in primary mouse osteoblasts undergoing differentiation. These data have been described in detail previously (29) and are freely available from the Gene Expression Omnibus (GSE54461). For details, see Supplemental Methods.

In-silico Annotation and Enrichment Analyses

Since all GWS and suggestive SNPs were non-coding (either intronic and intergenic SNPs), as were all SNPs in high LD with them, we annotated potential regulatory functions of those SNPs based on experimental epigenetic evidence including chromatin states, DNAse hypersensitive sites, histone modifications, phylogenetic conservation, altered regulatory motifs for transcription factor binding sites in human tissues, primary cells and cell lines from the ENCODE Project and the Roadmap Epigenomics Project (30,31). This was done by searching the HaploReg4 web browser. (32) Position weight matrices (PWMs) of a motif sequence were scored for instances that passed a threshold of $p < 4 \times 10^{-7}$. Only instances where a motif in the sequence passed the threshold of a PWM in either the reference or the alternate genomic sequence with variable nucleotide(s) (thus changing the PWM score) were considered. The enhancer and promoter states were obtained by ChromHMM (33) and were visualized using the WashU Epigenome Browser (http://epigenomewidget.epigenomegateway.wustl.edu/).

To evaluate whether top-associated SNPs were enriched with regulatory elements in specific tissues (such as bone relevant tissues, including primary osteoblast, bone-marrow-derived stem cell, or mesenchymal progenitor cells available in the ENCODE and the Roadmaps Epigenomics Project), a
A hypergeometric test was performed and permutation was used to estimate enrichment p-values. Since our imputation was based on the reference panel that is not generated by whole genome sequencing (international HapMap Project Phase II reference panel), we expected that our top associated SNPs may predominantly serve only as surrogate markers that are in high LD with the un-genotyped and un-imputed functional SNPs that are responsible for GWAS signals. Therefore, we extended our in-silico functional annotation and enrichment analysis to those common SNPs (MAF > 1% based on 1000 Genomes Project Phase I version 3 CEU references) that are in high LD ($r^2 > 0.8$ based on 1000 Genomes Project Phase I version 3 CEU references) with the most significant SNP in each locus.

**RESULTS**

**BMD and Fracture Associations**

Five loci had genome-wide significant (GWS, $p < 5 \times 10^{-8}$) associations with trabecular volumetric BMD (vBMD) in the meta-analysis of discovery (6 cohort studies) and replication cohorts (2 cohort studies, combined $N=15,275$). These included four loci marked by common SNPs (MAF $\geq 5\%$) located in 1p36.12 (near WNT4, ZBTB40), 1p43 (GREM2), 8q24 (TNFRSF11B), and 13q14 (TNFSF11, Table 1). All except for GREM2 have been previously associated with lumbar spine areal BMD. In addition, in the 5p13 locus, which has not previously been linked to lumbar spine BMD, the most significantly associated SNP with trabecular vBMD was rs2468531 (MAF = 3%). All GWS SNPs were intronic or intergenic (Supplemental Figure 3). There was no significant heterogeneity of effect sizes between sexes for these SNPs (Supplemental Figure 4). All GWS SNPs associated with trabecular vBMD were also strongly associated with integral vBMD and had similar effect sizes, although not all of the trabecular vBMD GWAS SNPs achieved genome-wide significance for integral vBMD, perhaps because of the smaller sample size with integral vBMD measurements (Supplemental Table 3). An additional 6 loci had common SNPs with suggestive-significant associations ($5 \times 10^{-8} < p < 5 \times 10^{-6}$) with trabecular vBMD, and only one of these (6q25) reached a suggestive significance level for integral vBMD (Supplemental Table 3). An additional 9 loci had SNPs that were suggestively associated with integral vBMD, though only 2 were suggestive after double GC adjustment (Supplemental Table 3). Among them, the most significantly associated SNP, rs3786178 (MAF = 2%) near CTIF on 18q21.2, had a relatively strong association (standardized $\beta = 0.19$, $p = 1.86 \times 10^{-6}$).

Among SNPs associated with trabecular vBMD or integral vBMD (listed in Table 1) with $p < 5 \times 10^{-6}$, only rs2468531 (5p13, near SLC1A3) was found to be associated with radiographic vertebral fracture after correction for multiple testing (odds ratio [OR] = 0.75 per minor allele, FDR p-value = 0.01, Table 2, Figure 2). The same SNP was nominally associated with clinical vertebral fracture (OR
= 0.66, p = 0.01, see the Lopez et al. manuscript attached to this submission, but FDR p = 0.07).
Among SNPs associated with trabecular vBMD (listed in Table 1), the GWAS SNP rs12742784 near ZBTB40 was associated with clinical vertebral fracture (OR = 0.82, FDR p = 7.4 x 10^-4). Although SNPs at other loci (GREM2, C6orf97, ATP2B1) were nominally significantly associated with vertebral fracture, no other ORs were nearly as strong as for rs2468531 or rs12742784 (Table 2).

cis-Expression Quantitative Trait Loci (cis-eQTLs) in Human Bone Biopsies
The cis-eQTL results of the whole bone biopsies are shown in Table 3. For genome-wide significant SNPs, we found two significant eQTLs after multiple testing correction. First, SNP rs12742784 in the 1p36.12 locus was associated with increased expression of EPHB2, about 355 kb downstream (β = 0.12, FDR p = 1.72x10^-3), but was only marginally associated (p = 0.08) with ZBTB40, the nearest gene in this GWAS locus (about 96 kb downstream). The other significant cis-eQTL finding was for SNP rs2468531 in the 5p13 locus, which was associated with increased expression of SLC1A3, 126 kb downstream from the associated SNP (β = 0.28, FDR p = 0.01). A suggestive SNP, rs2941584, was associated with EML6 expression in the 2p21 locus (FDR p = 0.04); and a suggestive SNP rs7301013 with WNT5B expression in the 12p13.3 locus (FDR p = 0.01). In most cases, the most significantly associated cis-eQTL gene in each locus was not the gene nearest to the top associated SNP, a phenomenon also observed in other studies(34). CCDC91 was filtered out due to low signal values in the microarray.

Expression in Mouse Osteoblasts
Ten of the eleven genes located near a trabecular vBMD locus or implicated through eQTL analysis were expressed during murine osteoblastogenesis, and each presented with a unique level and/or pattern of expression. EphB2 maintained a consistent level of expression over time, whereas Slc1a3 expression rose rapidly through the period of rapid cell proliferation and reached a plateau coincident with a phase associated with increased expression of extracellular matrix genes (~day 8-10, Supplemental Figure 5). Of the two genes near 1q43, Grem2 expression was extremely high during the period of cell culture associated with rapid growth and cell division. Expression of this gene decreased and entered a steady state plateau at about day 8 post differentiation. Like Grem2, Fmn2 showed a pattern of decreasing expression during osteoblastogenesis; however, expression of this gene was very low at all points examined. Both Akap11 and Zbtb40 demonstrated constant expression during osteoblast maturation (Supplemental Figure 5).
**In-silico** Annotation of Non-Coding SNPs and of SNPs in LD with the Top Associated SNPs

Evaluation of whether the top-associated SNPs (from Table 1) were enriched with regulatory elements in specific tissues showed the most significant enrichment for the cortex derived primary cultured neurospheres (E053) with enrichment p-value = 9.56x10⁻³. We observed 3 SNPs (out of 12) overlapping with regulatory elements in the cortex neurospheres (ENCODE, Supplemental Tables 4 and 5), compared to the 0.5 expected SNPs overlapping with regulatory elements in the same cell type if we randomly select 12 SNPs with the same MAF and LD pattern across the whole genome. After multiple testing corrections by FDR, the enrichment in the cortex neurospheres became non-significant.

Two common nonsynonymous SNPs were found to be in LD with the top associated SNPs. SNP rs2073618 (N3K) (discovery p-value=1.41 x 10⁻⁶) in TNFRSF11B is in high LD (r²=0.88) with rs1485303, and SNP rs35737760 (D859E) in CACNA1E is in high LD with SNP rs7301013 that was suggestive for integral vBMD. However, both variants were predicted not to affect protein function due to the corresponding amino acid substitution based on the conservation-based SIFT package and were predicted to be benign by PolyPhen-2. All common SNPs in high LD with top associated SNPs in all other loci were either intronic or intergenic. Twelve of the 21 loci with GWS or suggestive trabecular vBMD or integral vBMD associations had SNPs in LD that were located in either predicted enhancer or promoter regions in one of the three bone-relevant cell types: osteoblast primary cells, mesenchymal stem cell derived chondrocyte cultured cells, and bone marrow derived mesenchymal cultured cells (E129, E049 and E026, Supplemental Table 5). These included intronic or intergenic SNPs in the GWS trabecular vBMD loci near GREM2, TNFRSF11B, and TNFSF11, as well as the 5p13 locus. Of note, the GREM2 locus (1q43) has quiescent annotations across an abundance of cell types except for 2 SNPs, rs1414660 (r² for LD with top vBMD SNP = 0.87; discovery p-value=2.01 x 10⁻¹⁰) and rs9659023 (not analyzed), which are both located in an enhancer region that is specifically active in bone marrow derived mesenchymal cells, osteoblasts and other mesenchymal cells, suggesting a cell-type specific gene regulation in those bone-relevant cells. The rs1414660 regulatory sequence is under evolutionary constraint, as estimated by GERP and SiPhy (http://www.broadinstitute.org/mammals/haploreg/detail_v4.1.php?query=&id=rs1414660). Furthermore, the rs1414660 intronic single nucleotide change was predicted to perturb conserved regulatory motifs for bone-relevant transcription factors, such as CEBPa, CEBPb and others (Supplemental Table 6). The 5p13 locus is quiescent except for a region surrounding the indel rs148073475 (http://www.broadinstitute.org/mammals/haploreg/detail_v4.1.php?query=&id=rs148073475).
evaluate whether these 12 SNPs in LD with variants are specifically located in enhancer regulatory regions for three bone-relevant cells we tested for enrichment in regulatory regions in tissues other than bone relevant tissues. We performed hypergeometric tests in 127 cell types and tissues from the Roadmap Epigenomics Project but did not find significant enrichment, suggesting that these selected SNPs are enriched only in bone-specific gene regulatory regions.

DISCUSSION

Through these meta-analyses of vertebral trabecular vBMD and fracture, we identified two loci associated with lumbar spine BMD, vertebral fracture, and human bone expression of genes that were also expressed in mouse osteoblasts. One is a novel BMD locus, at 5p13, and the minor alleles of the most significantly associated SNPs had a lower frequency (3%), stronger positive associations with trabecular vBMD (β = 0.22), and lower risk of fracture (OR = 0.75) than did other variants associated with BMD or fracture in this study. Cis-eQTL analyses in human bone and mouse osteoblast expression studies suggest that the SLC1A3 gene, which is ~126 kb upstream of SNP rs2468531, may be the gene in this locus involved in bone modeling/remodeling. Common variants in another locus, 1p36.12, were significantly associated with trabecular vBMD, fracture (clinical vertebral OR: 0.82, FDR p = 7.4 x 10^{-4}) and expression of EPHB2, providing an explanation for the associations with BMD phenotypes consistently reported in this region(8,35-37). This is the first study to link EPHB2 expression to vertebral phenotypes in humans. The finding that these loci are associated with both vertebral trabecular BMD and vertebral fracture reinforces their clinical importance. Our expression studies suggest a regulatory function for the causal variants underlying these SNP associations.

SLC1A3: Previous studies have reported that the SLC1A3 gene is involved in glutamate signaling necessary for osteogenic response to mechanical loading.(38) SLC1A3 (aka GLAST or EAAT1) is a glutamate transporter expressed in human as well as rat and mouse osteoblasts and osteocytes, discovered through its down-regulation in osteocytes in response to osteogenic mechanical loading(39). SLC1A3 has been found to be expressed in most human tissues/cells, especially in brain and neurons. Although a Slc1a3 mouse knock-out showed no differences in multiple femoral bone phenotypes through age 6 months,(40) there has been no examination of either vertebral bone phenotypes or of aged mice in such a knockout. These are important distinctions, as Slc1a3 knockout effects on another phenotype have been shown to depend on advanced age,(41) and axial and appendicular skeletal regions are known to have distinct patterns of development and regulation over the course of development (e.g., (42-44)).
SLC1A3 associations have not been reported to be genome-wide significantly associated with aBMD in any previous study. In the most recent lumbar spine aBMD GWAS meta-analysis, the most significant SNP in this locus was rs2468531 (MAF=4.8%, β = 0.077, p = 7.4 x 10^{-3}) (29). That aBMD GWAS meta-analysis had much larger sample size and included many of the participating studies in our CT GWAS meta-analysis. It is unclear whether the difference in phenotype or underlying population differences contributed to this discrepancy. Previously reported cell and animal model evidence for SLC1A3 suggests its biological function in bone physiology may interact with mechanical loading and aging; therefore, it may be fruitful to evaluate such interactions with potentially causative SLC1A3 SNPs in future studies.

**EPHB2:** Our findings suggest that regulation of the Ephb2 gene contributes to the previously reported associations with BMD and fracture at the 1p36.12 locus. ZBTB40 has been consistently linked to both spine and hip BMD as well as fracture risk(8,35-37) but has an unknown role in bone development or maintenance. ZBTB40 was expressed in osteoblasts in our study, but the associated (intergenic) SNP was unrelated to any regulatory element in ENCODE. This gene is often reported concurrently with WNT4 associations with BMD; however, LD patterns and conditional analyses support the existence of two separate signals in this region of chromosome 1p36.12(8). In addition, cis-eQTL analysis did not find significant associations between GWAS SNPs and ZBTB40 and WNT4 gene expression in whole bone. On the other hand, a cis-eQTL in this locus was found for the EPHB2 gene. The EPHB2 gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. Several in vitro and animal studies have found that Ephb2 is involved in bone development,(45) homeostasis,(46) and fracture repair(47), as well as skeletal response to PTH(48) and IGF(49). This is the first study to link genetic variation in humans to EPHB2 expression and clinically important vertebral phenotypes.

**GREM2:** One additional locus associated with trabecular vBMD, an intronic SNP, rs9661787, in FMN2 and near GREM2, has not previously been reported for lumbar spine BMD by DXA. It has, however, been linked to trabecular BMD of the distal tibia, as measured by peripheral quantitative CT (pQCT), and was demonstrated to affect trabecular number and thickness as evaluated by HRpQCT.(50) In the current analyses, the FMN2/GREM2 SNP was also associated with integral vBMD with a similar effect size, perhaps because of the sizeable contribution of trabecular vBMD in the overall measure of integral vBMD by CT of the lumbar spine. The homologous region in mice (174.8 Mb on Chromosome 1) has consistently been associated with BMD phenotypes, including vertebral BMD.(51) In addition, our GWAS SNP rs9661787 in the FMN2/GREM2 locus is in high LD (r^2=0.88) with a GWAS SNP (rs9287237) identified previously for a pQCT GWAS.(50)
rs9287237 had similar effect sizes to our top SNP for trabecular vBMD and integral vBMD in this study.

SNP rs9287237 was robustly associated with GREM2 expression in human osteoblasts.(50) Each additional T allele of rs9287237 was associated with decreased expression of GREM2 in human osteoblasts, increased trabecular BMD and decreased fracture risk.(50) In our eQTL analysis, we also found SNP rs9287237 was associated with lower GREM2 expression in human whole bone biopsies, though the association was not statistically significant. GREM2 (aka PRDC and Gremlin2) is an extracellular antagonist of bone morphogenetic proteins (BMPs), and loss of this factor allows for an increase in osteoblastic differentiation.(52-54) We observed a marked decrease in expression of Grem2 as these cells transitioned from a committed but immature cell to a fully mature osteoblast in mouse. This suggests that Grem2 is an inhibitor of osteoblast maturation and/or function and that expression of this gene must be reduced to allow this process to occur. Our observation that GWAS SNP rs9661787 was associated with lower GREM2 expression (Table 3) and associated with higher trabecular vBMD (Table 1, G allele of rs9661787) supports previous findings that Grem2 inhibited osteoblast maturation and/or function. Available data suggest that this gene is not expressed or is only marginally expressed in mouse osteoclasts (http://biogps.org). Unlike for Grem2, expression of Fmn2 was barely detectable in osteoblasts. This low/lack of expression of this gene in bone has been corroborated in other studies wherein whole bone, osteoblasts, osteoclast and osteoblast like cell lines were examined (http://biogps.org). Together these data suggest that GREM2 is the more likely candidate at this locus.

Four other loci had common SNPs that were genome-wide significantly associated with trabecular vBMD (near WNT4, ZBTB40, TNFRSF11B, and TNFSF11), although effect sizes were much smaller than for the 5p13 locus. These loci have been consistently reported to be associated with lumbar spine BMD by DXA(8,28,29) and fracture.(10) The roles of WNT4, TNFRSF11B, and TNFSF11 are well described in WNT-signaling and RANK/RANKL/OPG pathways, which are central to bone metabolism.(55) Of particular relevance to our phenotype of spine BMD in older age, Wnt4 has been demonstrated to prevent bone loss and one of its common causes, inflammation, by inhibiting NF-κB in macrophages and osteoclast precursors.(56) The SNP, however, is predicted not to be constrained by SIFT and is benign by PolyPhen-2.

**Phenotypic considerations**

Volumetric BMD measured by CT has advantages over DXA BMD for evaluating genetic regulation specific to 3D structure and mineral density. CT measures allow for the removal of bone...
size from the phenotype, whereas DXA BMD is a 2D measured combination of size and density. Furthermore, DXA BMD of the lumbar spine includes the vertebral body and posterior elements, as well as other regions that are predisposed to degenerative changes. Volumetric BMD measures, including trabecular and integral BMD, were more strongly associated with prevalent vertebral fracture than was areal spine BMD in a case-control study nested in the Framingham Osteoporosis Study. (11) Therefore, vBMD may be a more relevant phenotype for vertebral fracture risk. Although candidate gene analyses have discovered distinct associations with, e.g., vBMD and vertebral cross-sectional area (57), ours is the first GWAS of volumetric phenotypes in a multi-cohort meta-analysis and the first to link vBMD SNP associations to fracture and gene expression.

Limitations

Limitations of the study include a relatively small number (15,275) of participants with volumetric BMD phenotypes available. As a polygenic and complex trait, BMD requires very large sample sizes to detect the effect sizes often observed for common SNPs. Of 49 loci associated with lumbar spine BMD in previous large GWAS meta-analyses, (8, 29) we identified only 9 in our volumetric spine BMD traits. Whether this lack of confirmation of previously identified spine BMD associations is due to true phenotypic differences in association or simply lower sample size in the current study is unknown. However, 4 out of 6 trabecular vBMD GWAS loci found in the current study have been reported by previous BMD GWAS meta-analysis; and 4 out 6 trabecular vBMD suggestive GWAS loci have also been reported by a previous DXA-derived BMD GWAS meta-analysis, suggesting limited statistical power with relatively smaller sample size may play a major role in this lack of confirmation. Further investigation of the involvement of those GWAS loci unique to the CT BMD will improve our understanding of the molecular regulation of bone.

Moderate effect size for most of the common SNPs may also contribute to the limited statistical power that the current study has. The majority of common variants previously reported are closer to zero (|standardized β| ≤ 0.03) than the range of effect sizes we observed for GWS associations with volumetric BMD (0.057 ≤ |standardized β| ≤ 0.098), implying lack of power in this study to identify common SNPs with smaller effect sizes. Similarly, the study was not designed to detect less common (1% < MAF < 5%) or rare variants (MAF < 1%), and only two variants with 2% ≤ MAF < 5% (SLC1A3 and CTIF) were found to be associated with trabecular vBMD or integral vBMD. These had effect sizes approximately three times as large as the more common variants and were similar in effect size to that reported for a low-frequency variant in EN1 for vertebral BMD. (29) again underscoring the value of studying less common variants for skeletal phenotypes. There are undoubtedly other genetic
contributors to BMD that will require studies powered to detect moderate effect sizes in low-frequency or rare variants.

Limitations regarding heterogeneous radiographic vertebral fracture definitions have been described(9) and may have limited our power for observing fracture associations among the vertebral-BMD associated loci. However, we observed similar prevalence of fracture across the cohorts that were included (16-22%), indicating that differences in case definitions may result in ascertainment of similar cases in these studies. Three trabecular vBMD loci (near ZBTB40, FMN2/GREM2, and SLC1A3) were associated more strongly with clinical vertebral fracture than with radiographic vertebral fracture, indicating a potential for clinical fracture to give a stronger association signal than radiographic fracture for these variants.

Several additional limitations of this study include limited statistical power to detect SNPs with moderate eQTL; imputation based on HapMap II reference panel rather than whole genome sequencing based 1000G reference panel, providing limited coverage of genetic variants across genomes; and limited bone-relevant tissues in existing databases for the in silico annotations of associated loci. In addition, pinpointing causal variants and functionally validating them in cellular or animal models remain to be done.

Despite these limitations, we identified novel vertebral BMD and fracture associations related to SLC1A3 and EPHB2 expression. We also confirmed the importance of GREM2 and several genes involved in WNT-signaling for trabecular BMD and vertebral fracture in large cohorts of older adults. Our study reinforces the benefit of large-scale GWAS of more refined and clinically relevant skeletal phenotypes and the need for continued evaluation of noncoding genomic variants with potential regulatory function.
References


This article is protected by copyright. All rights reserved


Table 1. Summary of associations with trabecular volumetric BMD (vBMD)

<table>
<thead>
<tr>
<th>Locus</th>
<th>Position (build 36)</th>
<th>SNP</th>
<th>Nearest gene(s) (distance in kb)</th>
<th>A1/A2</th>
<th>A1 frequency</th>
<th>Beta for A1</th>
<th>SE</th>
<th>Heterogeneity $I^2$</th>
<th>P value</th>
<th>Discovery (N=12,287)</th>
<th>Combined (N=15,275)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1p36.12</td>
<td>22444772 rs12755933</td>
<td>C/G</td>
<td>WNT4 (103)</td>
<td>0.27</td>
<td>-0.084</td>
<td>0.013</td>
<td>0.084</td>
<td>0.013</td>
<td>$2.66 \times 10^{-10}$</td>
<td>9.80 x 10^{-11}</td>
<td></td>
</tr>
<tr>
<td>1p36.12</td>
<td>22554953 rs12742784</td>
<td>C/T</td>
<td>ZBTB40 (96)</td>
<td>0.21</td>
<td>0.094</td>
<td>0.015</td>
<td>0.094</td>
<td>0.015</td>
<td>$1.18 \times 10^{-10}$</td>
<td>1.05 x 10^{-10}</td>
<td></td>
</tr>
<tr>
<td>1q43</td>
<td>238659259 rs9661787</td>
<td>C/G</td>
<td>FMN2 (0)-GREM2 (60)</td>
<td>0.81</td>
<td>-0.098</td>
<td>0.015</td>
<td>0.098</td>
<td>0.015</td>
<td>$1.26 \times 10^{-10}$</td>
<td>1.29 x 10^{-11}</td>
<td></td>
</tr>
<tr>
<td>5p13</td>
<td>36516441 rs2468531</td>
<td>G/C</td>
<td>SLC1A3 (126)-RANBP3L (179)</td>
<td>0.03</td>
<td>0.221</td>
<td>0.037</td>
<td>0.221</td>
<td>0.037</td>
<td>$1.47 \times 10^{-9}$</td>
<td>1.91 x 10^{-8}</td>
<td></td>
</tr>
<tr>
<td>8q24</td>
<td>120045437 rs1485303</td>
<td>A/G</td>
<td>TNFRSF11B (12)</td>
<td>0.44</td>
<td>-0.057</td>
<td>0.012</td>
<td>0.057</td>
<td>0.012</td>
<td>$7.35 \times 10^{-7}$</td>
<td>4.63 x 10^{-9}</td>
<td></td>
</tr>
<tr>
<td>13q14</td>
<td>41862203 rs17457561</td>
<td>A/G</td>
<td>AKAP11 (67) (TNFSF11 [700])</td>
<td>0.25</td>
<td>-0.095</td>
<td>0.014</td>
<td>0.095</td>
<td>0.014</td>
<td>$1.95 \times 10^{-12}$</td>
<td>1.12 x 10^{-11}</td>
<td></td>
</tr>
</tbody>
</table>

**Combined p < 5x10^{-8} for trabecular vBMD**

<table>
<thead>
<tr>
<th>Locus</th>
<th>Position (build 36)</th>
<th>SNP</th>
<th>Nearest gene(s) (distance in kb)</th>
<th>A1/A2</th>
<th>A1 frequency</th>
<th>Beta for A1</th>
<th>SE</th>
<th>Heterogeneity $I^2$</th>
<th>P value</th>
<th>Discovery (N=12,287)</th>
<th>Combined (N=15,275)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1p36.12</td>
<td>22444772 rs12755933</td>
<td>C/G</td>
<td>WNT4 (103)</td>
<td>0.27</td>
<td>-0.084</td>
<td>0.013</td>
<td>0.084</td>
<td>0.013</td>
<td>$2.66 \times 10^{-10}$</td>
<td>9.80 x 10^{-11}</td>
<td></td>
</tr>
<tr>
<td>1p36.12</td>
<td>22554953 rs12742784</td>
<td>C/T</td>
<td>ZBTB40 (96)</td>
<td>0.21</td>
<td>0.094</td>
<td>0.015</td>
<td>0.094</td>
<td>0.015</td>
<td>$1.18 \times 10^{-10}$</td>
<td>1.05 x 10^{-10}</td>
<td></td>
</tr>
<tr>
<td>1q43</td>
<td>238659259 rs9661787</td>
<td>C/G</td>
<td>FMN2 (0)-GREM2 (60)</td>
<td>0.81</td>
<td>-0.098</td>
<td>0.015</td>
<td>0.098</td>
<td>0.015</td>
<td>$1.26 \times 10^{-10}$</td>
<td>1.29 x 10^{-11}</td>
<td></td>
</tr>
<tr>
<td>5p13</td>
<td>36516441 rs2468531</td>
<td>G/C</td>
<td>SLC1A3 (126)-RANBP3L (179)</td>
<td>0.03</td>
<td>0.221</td>
<td>0.037</td>
<td>0.221</td>
<td>0.037</td>
<td>$1.47 \times 10^{-9}$</td>
<td>1.91 x 10^{-8}</td>
<td></td>
</tr>
<tr>
<td>8q24</td>
<td>120045437 rs1485303</td>
<td>A/G</td>
<td>TNFRSF11B (12)</td>
<td>0.44</td>
<td>-0.057</td>
<td>0.012</td>
<td>0.057</td>
<td>0.012</td>
<td>$7.35 \times 10^{-7}$</td>
<td>4.63 x 10^{-9}</td>
<td></td>
</tr>
<tr>
<td>13q14</td>
<td>41862203 rs17457561</td>
<td>A/G</td>
<td>AKAP11 (67) (TNFSF11 [700])</td>
<td>0.25</td>
<td>-0.095</td>
<td>0.014</td>
<td>0.095</td>
<td>0.014</td>
<td>$1.95 \times 10^{-12}$</td>
<td>1.12 x 10^{-11}</td>
<td></td>
</tr>
</tbody>
</table>

**Combined 5x10^{-8} ≤ p < 5x10^{-6} for trabecular vBMD**

<table>
<thead>
<tr>
<th>Locus</th>
<th>Position (build 36)</th>
<th>SNP</th>
<th>Nearest gene(s) (distance in kb)</th>
<th>A1/A2</th>
<th>A1 frequency</th>
<th>Beta for A1</th>
<th>SE</th>
<th>Heterogeneity $I^2$</th>
<th>P value</th>
<th>Discovery (N=12,287)</th>
<th>Combined (N=15,275)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2p21</td>
<td>54735125 rs2941584</td>
<td>C/T</td>
<td>SPTBN1 (0)</td>
<td>0.32</td>
<td>-0.060</td>
<td>0.012</td>
<td>0.060</td>
<td>0.012</td>
<td>$2.66 \times 10^{-12}$</td>
<td>1.29 x 10^{-7}</td>
<td></td>
</tr>
<tr>
<td>6q25</td>
<td>151897286 rs10872673</td>
<td>G/T</td>
<td>C6orf97 (40)</td>
<td>0.60</td>
<td>0.065</td>
<td>0.012</td>
<td>0.065</td>
<td>0.012</td>
<td>$5.92 \times 10^{-8}$</td>
<td>8.22 x 10^{-7}</td>
<td></td>
</tr>
<tr>
<td>12p13.3</td>
<td>2378832 rs7301013</td>
<td>A/G</td>
<td>CACNA1C (298)</td>
<td>0.83</td>
<td>-0.076</td>
<td>0.016</td>
<td>0.076</td>
<td>0.016</td>
<td>$3.94 \times 10^{-6}$</td>
<td>4.90 x 10^{-7}</td>
<td></td>
</tr>
<tr>
<td>12p12.1</td>
<td>28183168 rs12813778</td>
<td>A/G</td>
<td>CCDC91 (118)-PTHLH (167)</td>
<td>0.23</td>
<td>-0.068</td>
<td>0.014</td>
<td>0.068</td>
<td>0.014</td>
<td>$1.16 \times 10^{-6}$</td>
<td>2.35 x 10^{-6}</td>
<td></td>
</tr>
<tr>
<td>12q21.3</td>
<td>88861177 rs4842697</td>
<td>G/T</td>
<td>ATP2B1 (287)</td>
<td>0.57</td>
<td>-0.057</td>
<td>0.012</td>
<td>0.057</td>
<td>0.012</td>
<td>$9.09 \times 10^{-7}$</td>
<td>2.60 x 10^{-6}</td>
<td></td>
</tr>
<tr>
<td>16p13.3</td>
<td>315783 rs9921222</td>
<td>C/T</td>
<td>AXIN1 (27)</td>
<td>0.47</td>
<td>-0.059</td>
<td>0.012</td>
<td>0.059</td>
<td>0.012</td>
<td>$6.09 \times 10^{-7}$</td>
<td>4.90 x 10^{-7}</td>
<td></td>
</tr>
</tbody>
</table>

1 Locus zoom plots are in Supplemental Figure 3.

2 Observations were added by new genotyping in AGES (n=2,021) and/or by in silico replication in DHS (n=967). The SNP association was considered to be replicated if the addition of the replication sample to the meta-analysis did not result in a p > 5x10^{-8}.
Table 2. Associations with vertebral fracture for SNPs with combined $p < 5 \times 10^{-6}$ for trabecular volumetric BMD (vBMD)

<table>
<thead>
<tr>
<th>Locus</th>
<th>SNP</th>
<th>Nearest gene(s)</th>
<th>Morphometric vertebral fracture (N=21,701)</th>
<th>Clinical vertebral fracture (N=5,893)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>A1 frequency</td>
<td>OR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combined $p &lt; 5 \times 10^{-8}$ for trabecular vBMD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1p36.12</td>
<td>rs12755933</td>
<td>WNT4</td>
<td>0.26</td>
<td>0.99</td>
</tr>
<tr>
<td>1p36.12</td>
<td>rs12742784</td>
<td>ZBTB40</td>
<td>0.20</td>
<td>0.99</td>
</tr>
<tr>
<td>1q43</td>
<td>rs9661787</td>
<td>FMN2-GREM2</td>
<td>0.82</td>
<td>1.06</td>
</tr>
<tr>
<td>5p13</td>
<td>rs2468531</td>
<td>SLC1A3-RANBP3L</td>
<td>0.03</td>
<td>0.75</td>
</tr>
<tr>
<td>8q24</td>
<td>rs1485303</td>
<td>TNFRSF11B</td>
<td>0.43</td>
<td>1.03</td>
</tr>
<tr>
<td>13q14</td>
<td>rs17457561</td>
<td>AKAP11</td>
<td>0.24</td>
<td>1.02</td>
</tr>
<tr>
<td>Combined $5 \times 10^{-8} \leq p &lt; 5 \times 10^{-6}$ for trabecular vBMD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2p21</td>
<td>rs2941584</td>
<td>SPTBN1</td>
<td>0.31</td>
<td>1.03</td>
</tr>
<tr>
<td>6q25</td>
<td>rs10872673</td>
<td>C6orf97</td>
<td>0.59</td>
<td>0.94</td>
</tr>
<tr>
<td>12p13.3</td>
<td>rs7301013</td>
<td>CACNA1C</td>
<td>0.84</td>
<td>1.01</td>
</tr>
<tr>
<td>12p12.1</td>
<td>rs12813778</td>
<td>CDC91-PTHLH</td>
<td>0.23</td>
<td>0.98</td>
</tr>
<tr>
<td>12q21.3</td>
<td>rs4842697</td>
<td>ATP2B1</td>
<td>0.59</td>
<td>1.05</td>
</tr>
<tr>
<td>16p13.3</td>
<td>rs9921222</td>
<td>AXIN1</td>
<td>0.47</td>
<td>1.01</td>
</tr>
</tbody>
</table>

OR: odds ratio, FDR: false-discovery rate
Table 3. Summary of associations with gene expression in human bone biopsies

<table>
<thead>
<tr>
<th>Locus</th>
<th>Position (build 36)</th>
<th>SNP</th>
<th>Region</th>
<th>Nearest gene(s) (distance in kb)</th>
<th>Association with the nearest genes</th>
<th>The most significant cis-eQTL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Beta</td>
<td>P value</td>
</tr>
<tr>
<td>1p36.12</td>
<td>22444772</td>
<td>rs12755933</td>
<td>intergenic</td>
<td>WNT4 (103)</td>
<td>0.030</td>
<td>0.37</td>
</tr>
<tr>
<td>1p36.12</td>
<td>22554953</td>
<td>rs12742784</td>
<td>intergenic</td>
<td>ZBTB40 (96)</td>
<td>0.105</td>
<td>0.08</td>
</tr>
<tr>
<td>1q43</td>
<td>238659259</td>
<td>rs9661787</td>
<td>intronic</td>
<td>FMN2 (0)</td>
<td>0.027</td>
<td>0.27</td>
</tr>
<tr>
<td>5p13</td>
<td>36516441</td>
<td>rs2468531</td>
<td>intergenic</td>
<td>SLC1A3 (126)</td>
<td>0.279</td>
<td>4.36 x 10^{-3}</td>
</tr>
<tr>
<td>1p36.12</td>
<td>22444772</td>
<td>rs12755933</td>
<td>intergenic</td>
<td>WNT4 (103)</td>
<td>-0.107</td>
<td>0.33</td>
</tr>
<tr>
<td>5p13</td>
<td>36516441</td>
<td>rs2468531</td>
<td>intergenic</td>
<td>SLC1A3 (126)</td>
<td>0.279</td>
<td>4.36 x 10^{-3}</td>
</tr>
<tr>
<td>1p36.12</td>
<td>22444772</td>
<td>rs12755933</td>
<td>intergenic</td>
<td>WNT4 (103)</td>
<td>0.030</td>
<td>0.37</td>
</tr>
<tr>
<td>1q43</td>
<td>238659259</td>
<td>rs9661787</td>
<td>intronic</td>
<td>FMN2 (0)</td>
<td>0.027</td>
<td>0.27</td>
</tr>
<tr>
<td>8q24</td>
<td>120045437</td>
<td>rs1485303</td>
<td>intergenic</td>
<td>TNFRSF11B (12)</td>
<td>-0.019</td>
<td>0.61</td>
</tr>
<tr>
<td>13q14</td>
<td>41862203</td>
<td>rs17457561</td>
<td>intergenic</td>
<td>AKAP11 (67)</td>
<td>-0.068</td>
<td>0.03</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.035</td>
<td>0.28</td>
</tr>
</tbody>
</table>

**Combined p < 5 x 10^{-8} for trabecular vBMD**

**Combined 5 x 10^{-8} ≤ p < 5 x 10^{-6} for trabecular vBMD**

FDR: false-discovery rate
Figure 1. Cross-sectional view of the trabecular region of interest in the lumbar spine. Trabecular vBMD included this region only, while integral vBMD also included the cortical compartment. Both exclude the posterior elements that DXA measures of BMD incorporate, thus allowing CT measures to more precisely capture BMD of the vertebral body itself.

Figure 2. Beta coefficients and 95% CI for the additive effect of rs2468531 (SLC1A3) on trabecular vBMD (top) and morphometric vertebral fracture (bottom). Detailed study-specific results are provided in Supplemental Table 7.